Fast-growing CRO utilizes Veeva Vault Clinical
Suite to substantially decrease startup time
NEW
PROVIDENCE, N.J. and PLEASANTON,
Calif., May 30, 2023 /PRNewswire/ -- Veeva Systems
(NYSE: VEEV) today announced that Lotus Clinical Research expanded
its partnership with Veeva and broadened its adoption of Veeva
Vault Clinical Suite, a strategic move to strengthen its service
delivery and efficiency. This builds on Lotus' existing use of
Vault Clinical Suite to implement swifter and more connected
studies. The successful incorporation of Veeva Vault CDMS, Veeva
Vault eTMF, and Veeva Vault CTMS has effectively scaled Lotus'
trial operations while sustaining the highest quality standards.
With a unified clinical ecosystem, Lotus has significantly reduced
study startup time.
Lotus President, Bill Martin,
elaborated on the benefits of the partnership with Veeva, "This
collaboration enables Lotus to conduct a higher volume of clinical
trials while improving coordination with sponsors and clinical
trial sites. Easy-to-use, integrated clinical applications are
vital for Lotus as we continue to diversify our disease area
expertise and increase our site interactions and patient
recruitment."
As a rapidly expanding CRO, Lotus sought to develop an
adaptable, connected, and scalable infrastructure to keep pace with
its growth. The internal team of trained programmers is now
leveraging Vault CDMS, its primary clinical data management system,
to design studies entirely in-house. This has resulted in faster
delivery of electronic data capture (EDC) study builds,
significantly cutting study startup time.
Using integrated applications on a single platform has enabled
Lotus to effortlessly share questionnaires and metrics between
Vault CDMS and Vault CTMS, simplifying monitoring reports. With a
single source for documentation and a seamless flow of data and
documents across clinical applications, Lotus can increase
compliance, ensure rapid study initiation, and deliver a better
site experience. These advancements have propelled Lotus'
transition from a company with an initial focus on acute pain and
CNS to one that supports all facets of clinical research.
"We're proud to grow our five-plus year partnership with Lotus,
bringing together their experience and knowledge executing complex
clinical trials with our technology expertise," said Jon Young, director, Veeva Vault Clinical
strategy. "With Veeva Vault Clinical Suite, Lotus can provide
value-added services to customers and streamline how they work with
sites for greater speed and agility."
About Lotus Clinical Research
Lotus is a
scientifically driven, full-service, consultative CRO delivering
across all phases of clinical development with a legacy and focus
in CNS research. Since its inception in 2001, Lotus has
strategically focused the growth of its services, expertise, and
regulatory knowledge to successfully partner with biopharmaceutical
companies to execute clinical trials across all indications from
Phase 1 through 4.
Lotus is unique to other CROs in that they are owned by Emerge
Holdco, LLC, which also owns Evolution Research Group, LLC (ERG), a
leading clinical site organization with 20+ wholly owned clinical
research sites around the US, with over 450 beds, conducting early
and late phase complex trials in both healthy volunteers and highly
specialized, diverse populations. The successful conduct of
clinical trials at Lotus is a result of the therapeutic expertise
and the superior level of talent across the medical, operational,
and support functions. For more information, visit lotuscr.com.
About Veeva Systems
Veeva is the global leader in
cloud software for the life sciences industry. Committed to
innovation, product excellence, and customer success, Veeva serves
more than 1,000 customers, ranging from the world's largest
biopharmaceutical companies to emerging biotechs. As a Public
Benefit Corporation, Veeva is committed to balancing the interests
of all stakeholders, including customers, employees, shareholders,
and the industries it serves. For more information,
visit veeva.com.
Veeva Forward-looking Statements
This release contains forward-looking statements regarding
Veeva's products and services and the
expected results or benefits from use of
our products and services. These statements are based on
our current expectations. Actual results could differ
materially from those provided in this release and we have no
obligation to update such statements. There are numerous
risks that have the potential to negatively impact
our results, including the risks and uncertainties disclosed
in our filing on Form 10-K for the fiscal year ended January 31, 2023, which you can
find here (a summary of risks which may impact our
business can be found on pages 9 and 10), and in our subsequent SEC
filings, which you can access at sec.gov.
Contact:
Deivis Mercado
Veeva Systems
925-226-8821
deivis.mercado@veeva.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lotus-clinical-research-expands-partnership-with-veeva-to-accelerate-clinical-trials-301836185.html
SOURCE Veeva Systems